Baidu
map

Blood:阿巴西普(abatacept),一种新型免疫调节剂,可明显改善类固醇耐药性慢性移植物抗宿主病患者预后

2018-03-17 MedSci MedSci原创

类固醇耐药性慢性移植物抗宿主病(SR-cGVHD)仍然是同种异体移植后导致发病率和死亡率的主要原因。所以目前迫切需要探索治疗SR-cGVHD的新的免疫抑制疗法。现有开发出一种新型免疫调节剂,阿巴西普(abatacept),通过协同刺激阻滞抑制T细胞激活。近期Myrna R. Nahas等人进行一临床I期试验,对阿巴西普用于治疗SR-cGVHD的安全性、疗效和免疫作用进行评估。本研究采用3+3设计,

类固醇耐药性慢性移植物抗宿主病(SR-cGVHD)仍然是同种异体移植后导致发病率和死亡率的主要原因。所以目前迫切需要探索治疗SR-cGVHD的新的免疫抑制疗法。现有开发出一种新型免疫调节剂,阿巴西普(abatacept),通过协同刺激阻滞抑制T细胞激活。

近期Myrna R. Nahas等人进行一临床I期试验,对阿巴西普用于治疗SR-cGVHD的安全性、疗效和免疫作用进行评估。本研究采用3+3设计,阿巴西普有两种递增剂量:3mg/kg和10mg/kg,扩展队列予以10mg/kg。

研究结果显示阿巴西普耐受性良好,无剂量限制性毒性。本试验共评估了16位患者,其中44%的患者获得临床部分缓解(根据2005年NIH共识标准)。重要的是,阿巴西普可减少临床有反应者51.3%的强的松用量(起始平均27mg vs 14mg;p=0.01)。此外,在临床反应者中还观察到PD-1在循环CD4和CD8 T细胞中的表达量增加(p分别是0.009和0.007)。

总而言之,阿巴西普安全性好,并可显著提高NIH cGVHD评分、减少强的松用量。本研究结果提示阿巴西普有望成为SR-cGVHD的治疗药物,而且相关的II期临床试验正在进行中。

原始出处:

Myrna R. Nahas,et al.Phase I clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.Blood  2018  :blood-2017-05-780239;  doi: https://doi.org/10.1182/blood-2017-05-780239

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-09-21 xiaoyeshuang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-04-06 xuyong535
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-11-21 grace5700
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-07-13 xiaoyeshuang
  6. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-05-28 shanyongle
  7. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-04-17 日月
  8. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1779320, encodeId=6a8f1e7932046, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Sep 21 17:51:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745281, encodeId=55f01e452812e, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Fri Apr 06 20:51:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033695, encodeId=a16e2033695b0, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Nov 21 04:51:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691970, encodeId=6b7c16919e0c3, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 20 00:51:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778944, encodeId=4c4d1e7894413, content=<a href='/topic/show?id=c33118392a' target=_blank style='color:#2F92EE;'>#ACEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1839, encryptionId=c33118392a, topicName=ACEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Jul 13 00:51:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655849, encodeId=ed9116558499d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon May 28 20:51:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930302, encodeId=6ca71930302c5, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3226, encryptionId=87b8322658, topicName=BAT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Apr 17 07:51:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580853, encodeId=3501158085314, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620714, encodeId=74871620e144d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578846, encodeId=eee015e88467e, content=<a href='/topic/show?id=7e74536097a' target=_blank style='color:#2F92EE;'>#慢性移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53609, encryptionId=7e74536097a, topicName=慢性移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2dc16449103, createdName=丁鹏鹏, createdTime=Mon Mar 19 04:51:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map